ERBB2 and gastric cancer: On the basis of the results of the Trastuzumab for Gastric Cancer (ToGA) trial, trastuzumab plus chemotherapy has been approved as a first-line therapy for patients carrying Her-2 amplification, showing a median overall survival (OS) of 13.8 vs. 11.1 for anti-Her2 plus CT and the CT arm, respectively [26].